Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia

Despite significant progress made in the overall cure rate, the prognosis for relapsed and refractory malignancies in children remains extremely poor. Hence, there is an urgent need for studies that enable the timely selection of appropriate agents for Phase I clinical studies. The Pediatric Oncolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoeksema, Kimberley A, Jayanthan, Aarthi, Cooper, Todd, Gore, Lia, Trippett, Tanya, Boklan, Jessica, Arceci, Robert J, Narendran, Aru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176174/
https://www.ncbi.nlm.nih.gov/pubmed/21949608
http://dx.doi.org/10.2147/OTT.S21553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176174/
https://www.ncbi.nlm.nih.gov/pubmed/21949608
http://dx.doi.org/10.2147/OTT.S21553

Ejemplares similares